IL2 and cancer: Interleukin-2 was one of the earliest immunotherapy treatments, but the significant disadvantages associated with systemic IL-2 treatment have led to more sophisticated versions, capable of targeting the cancer (Rekers et al., 2018; Lieverse et al., 2020).